Acute management of MOGAD: therapeutic choices and clinical outcomes

1. Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is now recognized as a distinct inflammatory demyelinating disorder of the central nervous system (CNS), separate fr...

Authors

Institutions

Publication Details

Journal
Expert Opinion on Emerging Drugs
Published
2026-06-13
DOI
https://doi.org/10.1080/14728214.2026.2689745
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acute management of MOGAD: therapeutic choices and clinical outcomes

Eoin P. Flanagan, Edgar Carnero Contentti, Ethel Ciampi
Expert Opinion on Emerging Drugs
Multiple Sclerosis Research Studies
article

Acute management of MOGAD: therapeutic choices and clinical outcomes

Eoin P. Flanagan, Edgar Carnero Contentti, Ethel Ciampi
article en

Abstract

1. Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is now recognized as a distinct inflammatory demyelinating disorder of the central nervous system (CNS), separate fr...

Expert Opinion on Emerging Drugs
Pontificia Universidad Católica de Chile (CL), WinnMed (US), Christus Health (US), Instituto de Neurología Cognitiva (AR), Hospital Alemán (AR), Complejo Asistencial Sótero del Río (CL)
Good health and well-being
Openalex Percentile: Top 6%
Multiple Sclerosis Research Studies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.